Hop-on Inc. announced that an agreement has been reached with United Cannabis Corporation Inc. to assist with a regional rollout in the multibillion dollar Cannabis market utilizing their licensed partners' prolific catalog of CBD-dominant and THC:CBD strains and world class cultivation expertise. UCANN was selected as a strategic partner for their expertise in the medical and recreational Cannabis marketplace, their numerous regional partners that are state licensed and have been vetted for quality, consistency, and business ethics, and the fact that they are actively expanding from Colorado to other markets as they become viable. UCANN will assist in provisioning exclusive Cannabis cultivars that meet the stringent needs of Re-Medical's standardized cannabinoid profiles, and provide assistance in the build-out of processing, extraction, and production facilities, and regional sales and distribution operations for Re-Medical's cannabinoid therapies.

Re-Medical will provide licensing of intellectual property, where appropriate, regarding standardized cannabinoid profiles that show empirical or clinical efficacy as treatment for specific ailments, standardized cannabinoid profile extraction methods, efficient extraction of active ingredients from Cannabis using supercritical CO2 fluid extraction technologies, and the formulation and fabrication of transdermal and other innovative cannabinoid delivery technologies. The market for CBD and other cannabinoid therapies is just beginning to be tapped, with over $600 million in annual sales expected in 2014 in Colorado alone. With the entrance of more regions into the self-regulated cannabis marketplace, and the use of curated strains, professional production and processing methods, and rigorous testing standards, the market currently valued at $1.53 billion is projected to grow 68% to $2.57 billion by the end of 2014.